All lobbying filings

Capitol Counsel LLC

Capitol Counsel LLC filed a Q1 report for Alnylam Pharmaceuticals, Inc. on April 16, 2026, reporting $60,000 in lobbying income.

Lobbying for Alnylam Pharmaceuticals, Inc. · Pharmaceutical manufacturer.

As filed: CAPITOL COUNSEL LLC for ALNYLAM PHARMACEUTICALS, INC.

All filings by Capitol Counsel LLC · Everything Alnylam Pharmaceuticals, Inc. has reported

Filing · LD-2 quarterly report Q1 report

Reporting period

1st Quarter 2026

Jan 1 - Mar 31 · Posted Apr 16, 2026

Income

$60,000

What the client paid this registrant for the period.

Client based in

Massachusetts

Official filing document

Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Medical/Disease Research/Clinical Labs

Issues regarding FDA guidance on Platform Technology Platform Technology Designation Program for Drug Development.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.